8月以来,各大跨国药企(MNC)已经相继公布2025年上半年成绩单。强生(Johnson & Johnson)以456.36亿美元营收领跑,罗氏、默沙东依然位列前三。礼来凭借火爆的减重产品替尔泊肽实现业绩增长41%,一举跳跃至第六位。整体看,你追我赶的激烈竞争态势明显。专利悬崖下的亮眼成绩单未来几年,将有近200种药物失去专利保护,其中包括至少69种年销售额超10亿美元的重量级药物。这些专利悬崖对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.